Cormorant Asset Management’s Zymeworks ZYME Stock Holding History

Cormorant Asset Management’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-600,000	Closed	-$9.83M	–	84
2021 Q4	$9.83M	Sell	600,000 -350,000	-37%	-$7.3M	0.58%	44
2021 Q3	$27.6M	Sell	950,000 -371,936	-28%	-$12.4M	1.12%	28
2021 Q2	$45.9M	Sell	1,321,936 -678,064	-34%	-$21.5M	1.56%	19
2021 Q1	$63.2M	Buy	2,000,000 +800,000	+67%	+$32.5M	1.41%	16
2020 Q4	$56.7M	Buy	1,200,000 +50,000	+4%	+$2.32M	1.35%	27
2020 Q3	$53.6M	Buy	1,150,000 +600,000	+109%	+$20.6M	2.06%	16
2020 Q2	$19.8M	Sell	550,000 -150,000	-21%	-$5.52M	0.76%	42
2020 Q1	$24.8M	Hold	700,000	–	–	1.15%	29
2019 Q4	$31.8M	Buy	+700,000	New	+$25.4M	1.27%	27
2017 Q3	–	Sell	-232,008	Closed	-$1.94M	–	64
2017 Q2	$1.94M	Buy	+232,008	New	+$2.6M	0.32%	57

Other funds holding ZYME

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Cormorant Asset Management's ZYME Position: Q1 2022 in Review

Cormorant Asset Management sold out of Zymeworks (ZYME) in Q1 2022, closing a stake of 600,000 shares — an estimated $9.83M sold.

Cormorant Asset Management first reported a position in ZYME in Q2 2017 and held it in 10 quarters. The position peaked at $63.2M in Q1 2021. 120 funds tracked by Wall St. Rank hold ZYME as of Q1 2022.

Cormorant Asset Management reported no remaining Zymeworks position as of Q1 2022 after selling out during the quarter.
Cormorant Asset Management sold 600,000 Zymeworks shares in Q1 2022, an estimated $9.83M.
Cormorant Asset Management first reported a position in Zymeworks in Q2 2017 and held it in 10 quarters.
Cormorant Asset Management's Zymeworks position peaked at $63.2M in Q1 2021.
120 funds tracked by Wall St. Rank held Zymeworks as of Q1 2022.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.